Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate
As communicated earlier, Eurocine Vaccines is conducting preclinical trials to evaluate the mRNA and protein technology platforms for its therapeutic Herpes simplex virus type 2, HSV-2, vaccine candidates. The initial results demonstrate that immune responses in mice immunized with the mRNA candidate are not only non-inferior to those elicited by their protein counterpart. In fact, the mRNA vaccine generates superior T cell responses.Results from the study, comparing the two technology platforms at multiple doses, demonstrate that the mRNA and the protein vaccines were well tolerated and